On 18 March 2026, Sandoz announced it has entered into a licence, development and commercialisation agreement with Samsung Bioepis for up to five biosimilars, including vedolizumab.
Under the agreement, Sandoz will have exclusive rights to commercialise the biosimilars globally (excluding China, Hong Kong, Taiwan, Macau and the Republic of Korea), while Samsung Bioepis will be responsible for development, manufacturing and regulatory submissions in key markets.
The first biosimilar to be licensed under the agreement will be a biosimilar to Takeda’s Entyvio® (vedolizumab). In January 2026, Samsung Bioepis announced that it had a vedolizumab biosimilar under early-stage development.
Sandoz and Samsung Bioepis previously entered into a development and commercialisation agreement in September 2023 for Pyzchiva®/SB17, biosimilar to J&J’s Stelara® (ustekinumab). Under that agreement, Sandoz has the right to commercialise Pyzchiva® in Europe, Switzerland, the UK, the US and Brazil. Sandoz launched Pyzchiva® in Europe in July 2024 and in the US in February 2025.
In December 2025, the companies signed a commercialisation agreement for Epysqli™, biosimilar to Alexion’s Soliris® (eculizumab), for the Middle East and Africa region.